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A B S T R A C T
We report the evaluation of 265 compounds from a PDE-focused library for their antischistosomal activity,
assessed in vitro using Schistosoma mansoni. Of the tested compounds, 171 (64%) displayed selective in vitro
activity, with 16 causing worm hypermotility/spastic contractions and 41 inducing various degrees of worm
killing at 100 μM, with the surviving worms displaying sluggish movement, worm unpairing and complete ab-
sence of eggs. The compounds that did not affect worm viability (n=72) induced a complete cessation of
ovipositing. 82% of the compounds had an impact on male worms whereas female worms were barely affected.
In vivo evaluation in S. mansoni-infected mice with the in vitro ‘hit’ NPD-0274 at 20mg/kg/day orally for 5 days
resulted in worm burden reductions of 29% and intestinal tissue egg load reduction of 35% at 10 days post-
treatment. Combination of praziquantel (PZQ) at 10mg/kg/day for 5 days with NPD-0274 or NPD-0298 resulted
in significantly higher worm killing than PZQ alone, as well as a reduction in intestinal tissue egg load, dis-
appearance of immature eggs and an increase in the number of dead eggs.
1. Introduction
This study phenotypically evaluated the antischistosomal activity
potential of 265 compounds from a cyclic nucleotide phosphodiesterase
(PDE) focused library constructed by the PDE4NPD consortium (www.
PDE4NPD.eu), which focused on exploring PDEs as potential drug tar-
gets for several parasite species, including S. mansoni. Several PDE in-
hibitors are currently in use as therapeutic agents for various human
conditions, acting by targeting specific PDE isoenzymes and thereby the
breakdown of cyclic nucleotides (cAMP, cGMP) and thus prolonging
their biological effects (Ghosh et al., 2009). Pharmacologically, PDEs
gained great interest as drug targets for a large variety of clinical
conditions including their antiparasitic potential (Shakur et al., 2011).
The in vitro screening campaign used S. mansoni worm killing as the
primary parameter with in vivo follow-up evaluation of selected actives
in a mouse model.
Schistosomiasis has among the highest morbidity of the world's
neglected tropical diseases, causing an estimated 4,026,000 disability-
adjusted life years (DALYs). In socio-economic terms, public health
importance and prevalence in the developing world, it ranks second
only to malaria. More than 780 million people are at risk and ap-
proximately 261 million are infected in 78 countries of which 85%
reside in sub-Saharan Africa (WHO, 2017). No vaccine is yet available
and almost all control initiatives rely on praziquantel (PZQ), which has
been considered the drug of choice since the 1970s as it is highly ef-
fective after a single oral dose against all Schistosoma species that are
pathogenic to humans. In Egypt, as in most African countries, control
measures rely on campaigns of mass PZQ administration targeting high-
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risk groups (WHO, 2012). PZQ possesses positive features with respect
to safety, efficacy, cost and ease of distribution (Cioli et al., 2014) but
its efficacy is dependent on the age of the infection, the sex of the
worms and their paired or unpaired status (Pica-Mattoccia and Cioli,
2004). Immature worms (between 1 and 5 weeks after infection) are
much less sensitive to PZQ and hence such infections require re-treat-
ments. Moreover, findings denoting a possible threat of resistance de-
velopment were reported in mice under laboratory conditions (Fallon
and Doenhoff, 1994; Ismail et al., 1994; Sabra and Botros, 2008; Liang
et al., 2011) and during the intra-molluscan phase (Couto et al., 2011).
At the clinical level, reduced susceptibility to PZQ in S. mansoni field
isolates has been reported (Gryseels et al., 2001; William et al., 2001;
Cioli et al., 2004; Doenhoff et al., 2008; Melman et al., 2009; Mwangi
et al., 2014) but goes largely unnoticed in the mass-administration
campaigns, in part because of the insufficient efforts to monitor PZQ
resistance. For the above reasons, the search for new antischistosomal
agents represents an overriding priority. To date, a large number of
compounds have been identified as potential antischistosomal agents
but none has yet represented a suitable alternative to PZQ.
2. Materials and methods
2.1. Drugs and compounds
Praziquantel (PZQ) tablets (Distocide®) were obtained from
Egyptian International Pharmaceutical Industries Company (EIPICO).
The experimental compounds were prepared at University of
Amsterdam (VUA), University of Antwerp (UA) and Centro de
Investigaciones Biológicas (CIBeCSIC) and have a purity ≥95% by
HPLC. Synthesis of the imidazoles tested in vivo (NPD-0274, NPD-0298
and NPD-0264) was performed according to described procedures
(García et al., 2017).
2.2. Cytotoxicity on human lung fibroblasts
MRC-5 human lung fibroblasts were cultured in MEM medium
supplemented with 20mM L-glutamine, 16.5mM NaHCO3 and 5% fetal
calf serum (FCS). Assays were performed at 37 °C and 5% CO2 in 96-
well tissue culture plates with confluent monolayers. After 7 days of
incubation, cell viability was assessed after addition of resazurin and
Table 1
Compound prioritization of antischistosomal potency based principally on killing of mature S. mansoni worms in vitro and their toxicity to MRC-5 human lung
fibroblasts.
Serial No PDE
inhibitors
Worm killing at different concentrations (% of
total; male + female)
EC50 (μM) Uncoupling & complete
absence of eggs
Reduction in number of
eggs (%)
MRC-5
EC50
(μM)
100 μM 50 μM 25 μM 10 μM 5 μM 25 μM 10 μM 5 μM 25 μM 10 μM 5 μM
Killing from
50% to
100% (Class
I)
1 NPD-0274a 56 47 13 0 0 72 No No No 79 50 33 >64
2 NPD-0029 77 27 0 0 0 69 No No No 40 37 35 30
3 NPD-0356 50 39 14 0 0 89 No No No 60 10 0 60
4 NPD-0048 63 25 19 0 0 79 No No No 42 50 33 9
5 NPD-1012 62 0 0 0 0 99 No No No 67 32 38 ND
6 NPD-1246 100 53 0 0 0 50 Yes No No 100 20 10 >64
7 NPD-1253 50 37 0 0 0 91 Yes No No 100 21 29 35
8 NPD-2904 50 0 0 0 0 100 Yes Yes Yes 100 100 100 >64
9 NPD-1014 56 37 0 0 0 81 No No No 0 0 0 ND
10 NPD-1211 52 30 0 0 0 91 Yes No No 100 13 8 >64
11 NPD-1085 50 7 0 0 0 100 No No No 25 17 8 >64
12 NPD-1013 56 0 0 0 0 99 No No No 25 0 0 ND
Egg insult (Class
II)
13 NPD-0298a 16 0 0 0 0 >100 Yes Yes No 100 100 77 >64
14 NPD-0264a 6 0 0 0 0 >100 No No No 79 75 71 20
All compounds listed displayed 100% reduction in egg numbers with uncoupling at 100 μM and 50 μM.
a Compounds selected for in vivo testing. Yes: uncoupling and complete absence of eggs. No: no uncoupling and incomplete absence of eggs. ND, not determined.
Table 2
Percentage of male and female worm killing at different concentrations of test compounds.
Serial No PDE inhibitors % Worm killing
Male worms Female worms
100 μM 50 μM 25 μM 10 μM 5 μM EC50 male (μM) 100 μM 50 μM 25 μM 10 μM 5 μM EC50 female (μM)
Killing from 50% to 100% (Class I) 1 NPD-0274* 100 88 25 0 0 32 0 0 0 0 0 NE
2 NPD-0029 91 33 0 0 0 59 0 0 0 0 0 NE
3 NPD-0356 88 71 29 0 0 36 0 0 0 0 0 NE
4 NPD-0048 100 50 33 0 0 41 14 0 0 0 0 >100
5 NPD-1012 60 50 0 0 0 68 0 0 0 0 0 NE
6 NPD-1246 100 50 0 0 0 50 100 57 0 0 0 50
7 NPD-1253 100 66 0 0 0 49 0 0 0 0 0 NE
8 NPD-2904 73 0 0 0 0 97 0 0 0 0 0 NE
9 NPD-1014 100 67 0 0 0 49 0 0 0 0 0 NE
10 NPD-1211 88 56 0 0 0 48 56 13 0 0 0 93
11 NPD-1085 78 13 0 0 0 76 0 0 0 0 0 NE
12 NPD-1013 70 0 0 0 0 98 0 0 0 0 0 NE
Egg insult (Class II) 13 NPD-0298* 33 0 0 0 0 >100 0 0 0 0 0 NE
14 NPD-0264* 12 0 0 0 0 >100 0 0 0 0 0 NE
Controls: PZQ was 100% effective against both male and female worms at all concentrations tested (100, 50, 25, 10 and 5 μM), and DMSO (negative control, solvent;
0.125%–2%) had no effect on worm viability.
NE, no effect.
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fluorescence reading.
2.3. In vitro studies
2.3.1. Preparation of compounds
5mM stock solutions of PZQ and test compounds were prepared in
DMSO. At the day of experiment, 100 μM, 50 μM, 25 μM, 10 μM and
5 μM concentrations were freshly prepared in RPMI-1640 medium. All
compounds were initially tested at 100 and 50 μM; those showing worm
killing were further tested at 25, 10 and 5 μM.
2.3.2. Worm killing
Six to eight worms (obtained from Schistosome Biology Supply
Center (SBSC) of the Theodor Bilharz Research Institute (TBRI)), in-
cluding a minimum of one worm couple, were placed in each well of a
12-well tissue culture plate containing 2ml of fresh RPMI-1640
medium supplemented with glutamine, 20% newborn calf serum and
antibiotics (streptomycin, penicillin (2 ml/100ml) and gentamicin (200
μl/100ml)), and the indicated concentration of the test compounds
(Pica-Mattoccia and Cioli, 2004; Botros et al., 2005). The plates were
incubated overnight at 37 °C and 5% CO2. Worms were examined by
phase-contrast microscopy, 24 h after the start of the incubation, wa-
shed thrice with sterile saline, fresh medium was added and the in-
cubation was continued. After 48 h, worm motility was observed and
72 h later, medium was changed again. After 96 h (end of observation
period) worms were microscopically examined for motility and ap-
pearance. Each concentration was tested in duplicate. The final re-
cording of percent worm mortality was determined as the number of
dead worms [contracted and opaque] divided by the total number of
worms×100. Negative controls using pure medium without test
compound or medium with DMSO (2%), and positive control media
containing parallel concentrations of PZQ were tested in parallel. Im-
mature, early mature and mature S. mansoni worms were 3 weeks, 4
weeks and 6–7 weeks old respectively.
2.3.3. Worm ovipositing
Compounds showing worm killing, sluggish movement and/or un-
pairing were tested for inhibitory effect on ovipositing using 12-well
tissue culture plates with each well containing at least one worm
couple. Each concentration was tested in duplicate and eggs were
counted a first time after 72 h, upon which the eggs were discarded and
the medium changed. After 96 h (end of observation period), the newly
deposited eggs were counted and the total number was calculated for
each concentration tested.
Fig. 1. Effect of PDE inhibitors NPD-1012 and NPD-0356 on worm killing of different S. mansoni maturity stages.
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2.4. In vivo antischistosomal activity
2.4.1. Experimental infection of animals
Male Swiss albino mice (CD-1) obtained from SBSC and weighing
18–20 g were housed under environmentally controlled room tem-
perature of 20–22 °C, 12 h light/dark cycle and 50–60% humidity with
food and water ad libitum throughout the acclimatization and experi-
mental periods. Mice were infected with S. mansoni cercariae (provided
by SBSC) using body immersion (Liang et al., 1987) by exposure to
80 ± 10 cercariae/mouse. All the animal experiments were conducted
in accordance with the Guide for Care and Use of Laboratory Animals
and were approved by the Institutional Review Board of TBRI.
2.4.2. Test compounds and experimental design
NPD-0274, NPD-0298, NPD-0264 and PZQ were freshly suspended
in 2% Cremophore-EL (Sigma-Aldrich, St Louis, MO, USA). Infected
mice were divided into 8 groups: the first three groups were treated
with NPD-0274, NPD-0298 and NPD-0264, respectively, at 20mg/kg/
day for 5 days. Group 4 was treated with PZQ at 10mg/kg/day for 5
days. Groups 5, 6 and 7 were treated with each of the test compounds
combined with PZQ, each at 10mg/kg/day for 5 days starting from the
7th week post-infection. Group 8 was the vehicle control. To minimize
first-pass elimination, the CYP450 inhibitor aminobenzotriazole (ABT)
was administered at 100mg/kg/day for 5 days 2 h prior to each com-
pound administration. All drug administrations were performed orally.
2.4.3. Parasitological criteria for cure
Ten days post-treatment, all mice were sacrificed and perfused, and
the number of worms recovered (worm burden) was quantified and
sexed (Duvall and De Witt, 1967). The number of eggs per gram of liver
or intestinal tissue was counted (Cheever, 1968). The percentage of egg
developmental stages (oogram pattern) was studied (Pellegrino et al.,
1962), in which eggs at different stages of maturity (from I to IV) were
identified and counted. Mature eggs and dead eggs (granular, dark, and
semi-transparent) were also counted in three fragments of intestine and
the mean number of each stage was calculated.
2.5. Statistical analysis
The percentage reduction of worm or egg burden in each treated
group was calculated. The 50% effective concentration (EC50) or dose
(ED50) was calculated using Prism (GraphPad; Version 5.0) software
using a variable slope for the sigmoidal curve with an upper limit of
100%. Results are expressed as mean ± SEM. A two-tailed, unpaired
Student's t-test was used to detect the significance of difference between
the means of different groups. Results are considered significant if P
value is < 0.05.
3. Results
3.1. In vitro activity against S. mansoni
265 compounds from a PDE-targeting library were initially screened
for worm killing at 100 μM. Antischistosomal effects were recorded in
171 compounds (64%) as worm killing, sluggish worm movement,
unpairing, and absence or reduction in egg numbers; 16 resulted in
worm hypermotility/spastic contraction. Based on these in vitro find-
ings, the compounds were categorized into five classes: Class-I and eII
showed worm killing while the other three classes did not show worm
killing but impacted ovipositing, resulting in either a reduction or the
complete absence of eggs. Class-I compounds (12/171) showed worm
killing of 50–100% with EC50 values in the range of 50–100 μM
(Table 1). Class-I consisted of known PDE-like scaffolds, including
phthalazinones (4× ), imidazoles (2× ) and a quinazoline (Table S1).
Fig. 2. In vitro findings for selected compounds for in vivo experiments.
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These 12 hits were further investigated for dose-related worm un-
pairing, and reduction or complete absence of eggs. The Class-II com-
pounds NPD-0298 and NPD-0264, displaying strong effects on ovipo-
siting and slight effects on worm killing, were also included in the in
vitro follow-up study (Table 2).
All 14 compounds displayed 100% uncoupling of worm pairs with
complete absence of eggs at both 100 μM and 50 μM, and several even
impacted on egg numbers at 5 μM, a concentration with no effect on
worm viability at all. NPD-0298 and NPD-0264, which only had a slight
effect on viability at 100 μM, strongly reduced ovipositing down to
5 μM. For NPD-0298 this may be mostly explained through worm un-
coupling; for NPD-0264, however, there was no uncoupling below
50 μM while egg production was still severely affected. A similar pat-
tern was observed with NPD-0274 and some other compounds, in-
dicating a specific effect on egg depositing rather than on viability or
coupling (Table 1).
The above screening was conducted on mixed groups of males and
females where it was noted that the male worms were generally much
more severely affected than the female worms. We therefore re-ana-
lyzed worm killing for the hits in Table 1, this time performing parallel
incubations with male and female populations. Out of the 14 com-
pounds (Table 1), 11 displayed no activity on females even at 100 μM.
However, NPD-1246 had 100% worm killing on both sexes while NPD-
1211 displayed moderate effects at 100 μM (Table 2).
One of the major shortcomings of PZQ is its limited efficacy against
immature worms, which prompted us to look at the effect of the Class-I
compounds NPD-1012 and NPD-0356 against 3 week-old immature and
4 week-old early mature worms in comparison to the effects on mature
6 week-old parasites (Table 1). More prominent effects on early mature
and to a lesser extent on immature worms were noted at concentrations
of 50 μM and 25 μM compared to parallel findings in mature worms
(Fig. 1).
3.2. In vivo activity in the S. mansoni mouse model
Guided by the in vitro findings, three in vitro active 2, 4-ar-
ylimidazoles compounds, NPD-0274, NPD-0264 and NPD-0298 (Fig. 2),
were tested in S. mansoni-infected mice. Because these imidazole deri-
vatives had been reported to be metabolically unstable (Sebastián-Pérez
et al., 2018), concomitant dosing with the CYP450 inhibitor amino-
benzotriazole (ABT) (Watanabe et al., 2016) was carried out with each
experimental treatment (NPD, PZQ or combination of both). In a se-
parate experiment, ABT itself had no significant effect on worm burden
compared to untreated control mice (31.3 ± 1.3 (n=3) vs
29.0 ± 1.2 (n=6), p=0.28).
Treatment of S. mansoni-infected mice with the Class-I compound
Fig. 3. (A) Worm burden, (B) tissue egg load and (C) oogram pattern of NPD-0274 sacrificed 10 days post end of treatment when used alone at 20mg/kg/day or in
combination with PZQ at 10mg/kg/day for 5 days. ∗significantly different from infected control at P < 0.05, #significantly different from PZQ group at P < 0.05.
Numbers above columns and between parentheses represent % change from infected control group. ABT (100mg/kg orally) was administered 2 h prior to ad-
ministration of NPD-0274 and PZQ, whether alone or in combination. Error bars represent SEM.
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NPD-0274 at 20mg/kg/day for 5 days significantly decreased the worm
load and the intestinal tissue egg burden by 29% (P < 0.05) and 35%
(P < 0.05), respectively, as compared to the untreated controls
(Fig. 3A and B). Combination treatment with NPD-0274 and PZQ in
reduced doses of 10mg/kg/day each for 5 days revealed significantly
higher worm killing (96% vs 60%; P < 0.05), and higher intestinal
tissue egg burden reduction (83% vs 67%; P < 0.05) compared to PZQ-
treated alone (Fig. 3A and B). Interestingly, the maturation of eggs did
not change upon treatment with NPD-0274 alone (almost half the eggs
were immature or mature), but after the combination treatment only
very few mature eggs remained and the rest were dead (Fig. 3C).
With monotherapy of Class-I compound NPD-0247 yielding only
moderate relief of worm and egg burdens, it was decided also to eval-
uate the Class-II compounds NPD-0264 and NPD-0298, particularly
since in vitro NPD-0298 had impacted greatly on oviposition and cou-
pling (Table 1). Infected mice were given the same treatment dose and
schedule as the Class-I compounds. NPD-0264 did not reveal significant
antischistosomal activity, either alone or when combined with PZQ
(Fig. 4). NPD-0298 alone also did not reveal significant anti-
schistosomal activity. However, when co-administered with PZQ, worm
killing was significantly enhanced compared to PZQ alone (88% vs
60%; P < 0.05), intestinal tissue egg load was significantly reduced
(83% vs 67%) and the percentage of dead eggs was markedly increased
with complete absence of immature eggs (Fig. 5).
4. Discussion
From a PDE-focused library, 265 compounds were phenotypically
screened for antischistosomal efficacy and 171 (64%) displayed various
degrees of antischistosomal action revealed by worm mortality, motor
activity alterations (sluggish worm movement or spastic contractions),
reduced ovipositing and unpairing. The 171 ‘hits’ were sorted into five
classes based on their primary in vitro profile at 100 μM and 50 μM. At
100 μM, 12 (7%) displayed 50–100% killing (Class-I), and 29 (17%)
displayed< 50% worm killing but with worm unpairing, sluggish
movement of survivors and absence of eggs (Class-II). The reason why
the percentage of worm killing barely exceeded 50% was due to the fact
that almost all compounds mainly affected males with little or no im-
pact on the females, whereas PZQ was not sex-specific over the dose
range tested. As such, the EC50 values for males were substantially
lower than those for the mixed populations (Tables 1 and 2) with 32 μM
as the lowest EC50value, for NPD-0274. Disparities in in vitro drug
susceptibility between male and female S. mansoni worms have indeed
been previously reported. Higher susceptibility of male over female
schistosomes has previously been reported for PZQ, oxamniquine,
ginger extract, and some essential oils (Mikhail et al., 1978; Pica-
Fig. 4. (A) Worm burden, (B) tissue egg load and (C) oogram pattern of NPD-0264 sacrificed 10 days post end of treatment when used alone at 20 mg/kg/day or in
combination with PZQ at 10 mg/kg/day for 5 days. *significantly different from infected control at P < 0.05. Numbers above columns and between parentheses
represent percentage change from infected control group. ABT (100mg/kg orally) was administered 2 h prior to administration of NPD-0264 and PZQ, whether alone
or in combination. Error bars represent SEM.
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Mattoccia and Cioli., 2004; Mostafa et al., 2011; Tonuci et al., 2011).
Absolute killing of male worms only was also reported by Fernandes
et al. (2013) when the antischistosomal activity of different synthetic
preparations of N-alkylated diamines, amino alcohols, and glycosylated
amino alcohols were examined in vitro. Preferential killing of female
schistosomes has also been reported for some compounds, including 2-
(butylamino)-1-phenyl-1-ethanethiosulfuric acid, amino alkanethio-
sulfuric acids and artesunate (de Araújo et al., 2007; de Oliveira Penido
et al., 2008; Mitsui et al., 2009).
Many of the 171 test compounds, including those in Class-I and
Class-II, also induced motor activity alterations, which were usually
manifested as sluggish movement of the male worms. Spastic worm
contractions were observed with 16 compounds including only 1 from
Class-I (NPD-1014, a pyridazinone), but these contractions did not re-
sult in death during the in vitro observations. This phenotype has re-
cently been linked to inhibition of SmPDE4A (Long et al., 2017) and the
fact that few compounds in our PDE-focused library induced spastic
contractions may indicate that this particular PDE was not the main
target of most of the compounds. Indeed, the imidazole series that in-
cludes the hits NPD-0274, NPD-0264 and NPD-0298 is associated with
inhibition of the PDE10 family and has potential utility in Parkinson's
disease (García et al., 2017). Motor activity alterations are considered
important indicators of schistosomicidal activity, disturbing not only
the whole worm's muscle function and movement but also the muscles
of the suckers essential to attach to the host vessels and the tight pairing
of male and female worms (Ribeiro and Patocka, 2013; Patocka et al.,
2014).
Possibly the most important observation was the high impact on
ovipositing at very low, sub-lethal concentrations. Complete absence of
eggs is obviously expected in the presence of 100% worm killing or
separated worms (Magalhães et al., 2012). Reduction or absence of eggs
can also be expected when severe motor activity alterations are re-
corded as these disturb the muscle lining of the reproductive excretory
organs (Ribeiro and Patocka, 2013; Patocka et al., 2014). Complete
absence of eggs was recorded not only for Class-I and eII compounds,
but also after incubation with compounds displaying no schistosomi-
cidal activity, both in the presence of intact couples and after unpairing
(Class-III [14% of compounds] and Class-IV [28% of compounds]).
However, in some cases, cessation of ovipositing was observed without
any signs of motor disturbances in living, intact couples, which may
point to specific insult of the reproductive organs consistent with the
strong sex-specificity of the compounds.
Class-I compounds belong to several chemical families (Table S1).
Of particular interest were those bearing a phthalazinone or an
Fig. 5. (A) Worm burden, (B) tissue egg load and (C) oogram pattern of NPD-0298 sacrificed 10 days post end of treatment when used alone at 20mg/kg/day or in
combination with PZQ at 10mg/kg/day for 5 days. ∗significantly different from infected control at P < 0.05, #significantly different from PZQ group at P < 0.05.
Numbers above columns and between parentheses represent percentage change from infected control group. ABT (100mg/kg orally) was administered 2 h prior to
administration of NPD-298 and PZQ, whether alone or in combination. Error bars represent SEM.
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imidazole scaffold. The phthalazinones are related to the well-known T.
brucei PDEB1 and B2 inhibitors NPD-001 and NPD-008 (De Koning
et al., 2012; Veerman et al., 2016; Blaazer et al., 2017), while the
imidazoles are chemically related to previously described human
PDE10A inhibitors (García et al., 2017). As the imidazole scaffold
yielded several of the most active compounds and, as mammalian PDE
inhibitors, may be among the most likely inhibitors of helminth PDEs,
three imidazole derivatives were selected for evaluation in S. mansoni-
infected mice: one from Class-I (NPD-0274) and two from Class-II (NPD-
0264 and NPD-0298) (Fig. 2). The selection took into account factors
such as cytotoxicity and observed adverse effects in mice at fixed dose
regimens. Particular significance was given to the % reduction of egg
production, since the eggs cause the clinical pathology of schistoso-
miasis, as well as disease transmission. If ovipositing could be irrever-
sibly affected, the killing of the worm becomes of secondary im-
portance.
NPD-0274 showed a modest but significant reduction in worm
burden in vivo. In line with the in vitro effect on ovipositing rather than
worm viability, the other two imidazoles (NPD-0264, NPD-0298)
showed no significant worm killing in vivo. When administered at re-
duced doses with PZQ, NPD-0274 and NPD-0298 significantly en-
hanced worm killing (96% and 88% respectively, compared to 60%
killing for PZQ alone). The same combinations also showed a higher
reduction in intestinal egg load (both 83%, vs 67% for PZQ); of the eggs
that were still present, the vast majority was dead and none were im-
mature (i.e. viable and recently deposited). An increase of> 50% of
mature eggs with absence of one or more of the immature stages is
definite proof that a drug possesses antischistosomal activity
(Pellegrino et al., 1962). Combination therapy of PZQ and ox-
amniquine, omeprazole or mefloquine in experimental schistosomiasis
demonstrated increased worm lethality (Botros et al., 1989; El-Lakkany
et al., 2011; Keiser et al., 2011; Almeida et al., 2015). Information as to
whether drug combinations provide increased therapeutic efficacy over
monotherapy is scarce, although in the studies conducted to date no
curative advantages over single treatment were reported (Kamel et al.,
2000; Utzinger et al., 2003; Cui and Su, 2009).
In conclusion, this study enabled successful selection of several
antischistosomal compounds, based on in vitro findings such as worm
killing, unpairing, alterations of motor activity (sluggish worm move-
ment, spastic contractions) and ovipositing. Guided by these criteria,
three imidazole derivatives were administered alone and in combina-
tion with PZQ to S. mansoni infected mice, providing enhanced ther-
apeutic efficacy in combination with PZQ. When administered alone in
vitro, there was a clear reduction to complete absence of eggs with no
recovery over 7 days in the absence of drug, suggesting long-term
disabling of ovipositing. The near-complete eradication of viable eggs
with the PZQ/NPD-0274 and PZQ/NPD-0298 combinations is particu-
larly promising as it would greatly diminish or eliminate pathology and
above all transmission. It is the rapid reinfection caused by the failure
to break the transmission cycle that remains the most important factor
in the persistently high infection rates in endemic areas.
These imidazoles are structurally related to a family of human
PDE10A inhibitors and have also shown phenotypic activities in try-
panosomatids (Sebastián-Pérez et al., 2018; de Araújo et al., 2019).
Further developments will focus on additional SAR, on validating the
SmPDEs (particularly of the PDE10 family) as the targets for these
compounds, on transcriptomics to explain the observed sex differences
in drug susceptibility, and on pharmacokinetic studies to rationally
improve dosage regimens. The fact that these imidazoles are at least
equipotent against immature and early mature worms gives hope that
the most severe limitation of PZQ can be overcome.
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